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New understandings of the genetic basis of isolated
idiopathic central hypogonadism
Marco Bonomi1,2, Domenico Vladimiro Libri2,3, Fabiana Guizzardi2, Elena Guarducci4, Elisabetta Maiolo5,
Elisa Pignatti6, Roberta Asci7, Luca Persani1,2,3 on behalf of the Idiopathic CentralHypogonadismStudyGroup of
the Italian Societies of Endocrinology and Pediatric Endocrinology and Diabetes*
Idiopathic hypogonadotropic hypogonadism is a rare disease that is characterized by delayed/absent puberty and/or infertility due to an
insufficient stimulation of an otherwise normal pituitary–gonadal axis by gonadotrophin-releasing hormone (GnRH) action. Because
reduced or normal luteinizing hormone (LH)/follicle-stimulating hormone (FSH) levels may be observed in the affected patients, the
term idiopathic central hypogonadism (ICH) appears to be more appropriate. This disease should be distinguished from central
hypogonadism that is combined with other pituitary deficiencies. Isolated ICH has a complex pathogenesis and is fivefold more
prevalent in males. ICH frequently appears in a sporadic form, but several familial cases have also been reported. This finding, in
conjunction with the description of numerous pathogenetic gene variants and the generation of several knockout models, supports the
existence of a strong genetic component. ICH may be associated with several morphogenetic abnormalities, which include osmic
defects that, with ICH, constitute the cardinal manifestations of Kallmann syndrome (KS). KS accounts for approximately 40% of the
total ICH cases and has been generally considered to be a distinct subgroup. However, the description of several pedigrees, which
include relatives who are affected either with isolated osmic defects, KS, or normo-osmic ICH (nICH), justifies the emerging idea that
ICH is a complex genetic disease that is characterized by variable expressivity and penetrance. In this context, either multiple gene
variants or environmental factors and epigenetic modifications may contribute to the variable disease manifestations. We review the
genetic mechanisms that are presently known to be involved in ICH pathogenesis and provide a clinical overview of the 227 cases that
have been collected by the collaborating centres of the Italian ICH Network.
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INTRODUCTION
The physiological function of the human hypothalamic–pituitary–
gonadal (HPG) axis is based on the pulsatile release of the hypotha-
lamic gonadotrophin-releasing hormone (GnRH), which is secreted
into the hypophyseal portal circulation at the median eminence. The
interaction of GnRH with its specific receptor (GnRH receptor
(GnRHR)) on the pituitary gonadotropes stimulates the synthe-
sis and secretion of the two pituitary gonadotrophins: luteinizing
hormone (LH) and follicle-stimulating hormone (FSH). LH and
FSH activate gonadal activity and gametogenesis in both sexes.
GnRH-secreting neurons arise in the olfactory placode of the human
embryo and then migrate to their final destination in the mediobasal
hypothalamus to terminate their differentiation and initiate the secre-
tion of GnRH.1,2 Thismigration process is regulated by several factors,
including the spatiotemporal expression patterns of axonal guidance
cues, cell adhesion molecules, extracellular matrix proteins, and
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growth factors and neurotransmitters that determine the GnRH
neuronal fate.3 The correct development and coordinated function
of the GnRH-secreting neurons and the gonadotropes is essential
for the correct activation of the gonads during foetal life and the
neonatal period (the so-called ‘minipuberty’). After a dormant phase
during infancy and childhood, HPG activity is resumed at the time of
the puberty and throughout the adult reproductive age.
Central hypogonadism (CH) is either congenital or acquired, and it
can be secondary to hypothalamic or pituitary lesions. CHmay also be
isolated or combined with other pituitary hormone defects.4 Here, we
will focus on the isolated forms of CH that cause variable defects of
pubertal development and infertility; these forms are generally clas-
sified as idiopathic central hypogonadism (ICH). ICH is a disease with
a complex and still largely unknown pathogenesis that is caused by an
insufficient stimulation of an otherwise normal pituitary–gonadal axis
by GnRH action. In fact, ICH is biochemically characterized by low
levels of sex steroids (testosterone or estradiol) in the presence of low/
normal levels of gonadotrophins (LH and FSH). In patients with nor-
mal levels of circulating gonadotrophins, LH and FSH are not secreted
in a pulsatile manner and are therefore ineffective at the target level.5
ICH is a rare disease; its incidence is 1 : 8000 males and 1 : 40 000
females. It can be associated with either a normal or defective sense
of smell, which identifies normo-osmic ICH (nICH) or Kallmann
syndrome (KS), respectively. Males frequently present with defective
androgenisation and growth at a peripubertal age, but micropenis and
cryptorchidism may already be evident in the neonatal period, which
indicates a defective activation of HPG during prenatal development.
Females generally present with primary amenorrhea and growth
retardation. Additional neurological (e.g., anosmia) and non-neuro-
logical (e.g., midline or kidney defects) defects may frequently coexist,
and they can be linked to specific modes of inheritance. Indeed, KS
was originally thought to be caused by mutations in a specific X-
chromosome gene, KAL1,6–8 but this genetic defect was soon found
to be present in only a minority of the patients. Nevertheless, the
observation of familial cases with variable modes of ICH inheritance
(X-linked or autosomal dominant or recessive) soon indicated that
ICH retains a highly heterogeneous genetic component. The applica-
tion of conventional linkage studies to investigate the genetic basis of
ICH has proven to be difficult; most pedigrees tend to be small in size
because the majority of patients remain infertile without treatment.9 In
the past decade, however, key contributions (reviewed in Ref. 5) from
animal and cellular models, and genetic studies in a series of patients
have provided evidence of new genetic determinants of ICH (either
nICH or KS). These advances have played a significant role in the
elucidation of the pathophysiology of ICH, and they have helped to
discover the physiological complexities of the HPG axis.
GENETICS OF ICH
A multitude of candidate genes for ICH have been proposed, and a
tentative schematic representation of the various mechanisms that
can be disrupted by these genetic defects is reported in Figure 1.
Some genes are required for the correct embryonic differentiation
of the GnRH-secreting neurons, such as the receptor–ligand pair
FGFR1/FGF8 (fibroblast growth factor receptor 1 and fibroblast
growth factor 8), NELF (nasal embryonic LH-releasing hormone
Factor) and HS6ST1 (heparan sulphate 6-O-sulphotransferase 1).
Other genes encode the signals that are essential for the correct
migration of the GnRH neurons from their embryonic origin to
the hypothalamus, such as KAL1, the ligand–receptor complex
PROK2/PROKR2 (prokineticin 2 and its receptor) and CHD7 (chro-
modomain helicase DNA-binding protein 7). Other genes encode the
elements of upstream signals that contribute to the activation of the
GnRH neuron, such as the two ligand–receptor complexes that are
formed either by TAC3/TACR3 (tachykinin 3 and its receptor,
which is also named neurokinin B (NKB), and neurokinin 3 receptor
(NK3)) or KISS1/KISS1R (kisspeptin 1 and its receptor, which was
previously known as GPR54). Finally, candidate genes include the
GnRH gene itself (GnRH1) and its receptor (GnRHR).
Figure 1 Schematic representation of the genes implicated in HPG activation. In each step, the different genes whose genetic variants disrupt the HPG axis activity are
indicated. ARC, arcuate nucleus; CP, cribriform plate; GL, glomerulus; HPG, hypothalamic–pituitary–gonadal; M, mitral cell; ME, median eminence; ON, olfactory neurons.
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KAL1
The KAL1 gene (OMIM number: 308700), which is located on chro-
mosome Xp22.3, consists of 14 exons that encode an extracellular
matrix glycoprotein of approximately 100 kDa and is termed anos-
min-1. It consists of a cysteine-rich region, a whey acidic protein
domain and four fibronectin type III domains.6,7 The fibronectin type
III domains appear to create a flat surface with a strong basic charge,
which enables interactions to occur between anosmin-1 and other
components of the extracellular matrix.10,11 Anosmin-1 is expressed
in the human forebrain at 5 weeks of gestation at the area of contact
with the olfactory fibres and appears to stimulate afferent projections
to the olfactory bulb.12 A post-mortem study of a 19-week-old male
foetus with a deletion that included KAL1 provided important insights
into the pathology of X-linked KS; this study revealed both an absence
of olfactory bulbs and the abnormal migration of GnRH neurons that
had differentiated from the olfactory placode and had begun tomigrate
before they were arrested in a tangle of olfactory neurons at the point of
entry into the central nervous system.13 Various types of KAL1 gene
abnormalities have been reported in patients with KS. These abnor-
malities include missense and nonsense mutations, splice site muta-
tions, intragenic deletions and submicroscopic chromosomal deletions
involving the entire KAL1 gene.14 Clinical features in mutation-pos-
itive males include ICH and anosmia/hyposmia. In addition, several
non-reproductive and non-olfactory disorders are largely attributed to
KAL1 defects, including midline facial defects, such as cleft lip and/or
cleft palate, short metacarpals, renal agenesis, sensorineural hearing
loss, bimanual synkinesia, oculomotor abnormalities and cerebellar
ataxia.15 Of these defects, renal agenesis and bimanual synkinesis show
the highest incidences; they occur in approximately 30%–40% and
75% of KS cases, respectively.16 KAL1 mutations have been detected
in approximately 60% of patients with familial KS, which suggests an
X-linked mode of inheritance; they have been detected in only 10%–
15% of male patients with sporadic KS.14 Furthermore, nearly all
mutations have been identified in patients with both ICH and olfactory
dysfunction of variable extents. To date, only one case with nICH and a
KAL1 mutation has been reported in the literature.17
FGFR1 and FGF8
The FGFR1 gene (OMIM number: 136 350), which is also called
KAL2, is located on chromosome 8p12 and comprises 18 exons.
The mature FGFR1 protein belongs to the receptor tyrosine kinase
superfamily, and it consists of four subtypes (FGFR1–4) and seven
FGFR isoforms, which specifically bind to particular members of the
22 fibroblast growth factor (FGF) ligands. FGFR1 consists of three
extracellular immunoglobulin-like loops (D1, D2 and D3), an acid
box that is located between the first two immunoglobulin loops (the
D1–D2 linker region that contains a stretch of negatively charged
amino acids and a heparan sulphate-binding site within the first half
of D2), a transmembrane domain and an intracellular split tyrosine
kinase domain.18 Alternative splicing within the second half of the
juxtamembrane D3 domain generates two transmembrane isoforms,
IIIb and IIIc.19 The cognate FGF ligand binding is formed by the
proximal membrane D2 and D3 domains. The D3 isoform determines
ligand-binding specificity while the D1 domain can fold back to inter-
act with D2 in the FGF and heparan sulphate (HS) contact sites;
therefore, it functions as a potential competitive auto-inhibitor of
the interaction between FGFR and FGF and HS. FGFR1 signalling is
achieved by the induction of conformational changes in the receptor
upon ligand binding, which leads to dimerisation and the subsequent
activation by autophosphorylation of its intracellular tyrosine kinase
domains. In addition to requiring two FGF ligands, the binding of
heparin or HS proteoglycan is also essential for FGF receptor dimer-
isation and the activation of the FGF–FGFR complex.20 FGFR1 sig-
nalling has been shown to play a broad role during embryogenesis,
homeostasis and wound healing. Several studies on the expression
patterns of FGF ligands and receptors during central nervous system
development have indicated the critical role of FGF in the initial
generation of neural tissue.21 This activity is also present in the rostral
forebrain; it directly affects the olfactory bulb development, which
may influence the GnRH neuronal migratory activity.22 Fgfr12/2
knockout (KO) mice show persistent cell proliferation within the
anterior end of the telencephalon, and this leads aplasia in the olfact-
ory bulbs.22 Furthermore, a 30% decrease in the number of hypotha-
lamic GnRH neurons was observed in mice with dominant negative
Fgfr12/2 mutations that were targeted to GnRH neurons,23 and the
early emergence of GnRH neurons appeared to be disrupted in
Fgfr12/2 hypomorphic mice.24 Therefore, loss-of-function mutations
in FGFR1 result in a defect in GnRH neuron migration via the abnor-
mal morphogenesis of the olfactory bulb, while specific gain-of-
function mutations in FGFR1 cause craniosynostosis.25 Dode and
Hardelin16 first reported the association between FGFR1 loss-of-
function mutations and the dominant form of KS. Since that obser-
vation, several FGFR1 mutations, all of which occurred in the
FGFR1IIIc isoform and spanned all of the functional domains of
the receptor, have been identified in KS-affected individuals and
in patients with nICH.26,27 Similar to KAL1 defects, other non-
reproductive and non-olfactory disorders, such as cleft palate or lip,
dental agenesis and bimanual synkinesis, are associated with KS due to
FGFR1 defects.15 An important phenotypic variability has been
reported in mutated FGFR1 in unrelated probands and mixed pedi-
grees. The coexistence of KS, isolated hyposmia without hypogonad-
ism, and nICH was observed even in patients from the same family
that shared an identical mutation.28 The presence of modifier genes,
the involvement of multiple genes or an epigenetic mechanism may
explain this different phenotypic expression of the same genetic
defect.29 It is therefore evident that the precise quantitative regulation
of FGFR1 signalling is essential for normal development, and both
attenuated and increased signalling cause disparate phenotypes.
FGF family ligands consist of 22 structurally related proteins with
primary sequence differences that determine the FGF–FGFR-specific
interaction and thus regulate the diverse function of the FGF pathway.
At least 11 different FGFs can activate FGFR1, but FGF8 has been
identified as a key ligand for FGFR1IIIc in KS and nICH pathogen-
esis.30 Thus, the FGF8 gene (OMIM number: 600483), which is
located on chromosome 10q24, is also called KAL6. This role has been
confirmed in mice that are homozygous for an Fgf8 hypomorphic
allele; these mice had small telencephalons with no olfactory bulbs
in addition to other cardiac, craniofacial, forebrain, midbrain and
cerebellar developmental abnormalities, which included the absence
of GnRH neurons.24,30 Overall, these data demonstrate the crucial role
of FGF8-signalling activation through the assembly of the FGF8–
FGFR1–HS complex in the GnRH neuronal and olfactory system
development. Nevertheless, other FGF mutations can impair the
FGF–FGFR1 pathway and lead to ICH.
HS6ST1
During the preparation of this manuscript,HS6ST1, which is (OMIM
number: 604846) located on chromosome 2q21 and involved in extra-
cellular sugar modification, was indeed found to be mutated in
patients with ICH.31 HS polysaccharides are extracellular matrix
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components that modulate the cell–cell communications that are
important for neural development.32 This post-translational modi-
fication is important for the interaction and activation of the FGFR–
FGF complex20 and for the interaction of anosmin1 with the cell
membrane.10,11,33 The importance of these molecular interactions
has been confirmed in a model of transgenic nematodes that mis-/
overexpress the KAL1 orthologue in certain neurons; the axon-
branching phenotype was reversed inmutant worms that lacked either
HS6ST1 or C5-epimerase, which is another enzyme that is involved in
the biosynthesis of HSPS chains.34,35HS6ST1 appears to bemutated in
KS or nICHpatients with awide spectrumof severity and timing of the
onset of GnRH deficiency.31 Clinical variability is also evident both
within and across families that carry the same genetic alteration.31 All
of the identified HS6ST1 variants were also tested in vivo and in vitro,
and they displayed impaired activities in both assays.31
PROKR2 and PROK2
Another pair of receptor–ligand genes, PROKR2 (OMIM number:
607123), which is located on chromosome 20p13 and also called
KAL3, and PROK2 (OMIM number: 607002), which is located on
chromosome 3p21.1 and also called KAL4, were considered to be
potential causative genes of KS. The mutant mice that lacked
PROKR2, which is a transmembrane receptor interacting with the
heterotrimeric guanine nucleotide-binding proteins (G protein-
coupled receptor (GPCR)), presented abnormal olfactory bulb
development that was combined with severe atrophy of the reproduct-
ive system.36 The prokineticin system is composed of two nearly ident-
ical (approximately 85% gene homology) receptors (PROKR1 and
PROKR2) and their two polypeptide ligands, PROK1 and PROK2,
which show considerably less homology and exhibit quite different
anatomic distributions. Although PROK1 and its receptor, PROKR1,
are primarily restricted to the gastrointestinal system where they are
responsible for motility, PROK2 and PROKR2 have a more specific
neuroendocrine profile; they are located in the arcuate nucleus, olfact-
ory track and suprachiasmatic nucleus.37,38 In 2006, Dode´ et al.39
demonstrated that mutations in these pairs of ligand–receptor genes
cause human GnRH deficiency in patients with nICH or KS.
Subsequently, many mutations were described in the literature; most
of these mutations are missense mutations, and many are also present
in apparently unaffected individuals, which raises questions regarding
their pathogenic role in the disease. However, deleterious effects on
prokineticin signalling have subsequently been shown in vitro for
several variations.40,41 The finding of both heterozygous and
homozygous (or compound heterozygous) unrelated patients with
PROKR2 and PROK2 mutations39,42 is in favour of a possible oligo-
genic mode of inheritance in heterozygous patients, which has been
demonstrated in some cases.29,42 A variety of accessory features,
including fibrous dysplasia, sleep disorder, severe obesity, synkinesia
and epilepsy, have been noted in patients with PROK2 or PROKR2
mutations.40
KISS1R and KISS1
The human GPR54 gene (OMIM number: 604161) is located on
chromosome 19p13.3 and encodes a 398-amino acid GPCR whose
ligand binding-induced activation determines, via a Gq pathway,
the intracellular accumulation of IP3/calcium.43 GPR54 has been
shown to be the receptor for small peptides that are derived from
the KISS1 gene,44 which caused its recent redesignation as KISS1R.
The KISS1 gene (OMIM number: 603286), which is located on
chromosome 1q32, encodes a 145-amino acid precursor peptide,
kisspeptin 1, which produces four cleavage products: the longest
54-amino acid peptide, which is known as kisspeptin 54 or metas-
tatin (composed of amino acids 68–121) and three smaller products
of 14, 13 and 10 residues (kisspeptin 14, kisspeptin 13 and kisspep-
tin 10). All four peptides exhibit the same affinity and efficacy
towards KISS1R, indicating that the C-terminal end of the peptide
is responsible for the binding and activation of the receptor.44,45
Although all four kisspeptin products are biologically active,46 the
in vivo relevance of the shorter peptides is still unknown. KISS1R is
expressed in both the hypothalamus and pituitary, while KISS1 is
expressed only in the hypothalamus.44 Physiological and pharmaco-
logical studies have demonstrated the implication of the KISS1–
KISS1R complex in the HPG axis. Kiss1r2/2 KO mice show an
ICH phenotype with nearly absent sexual maturation even in the
presence of eutopic GnRH-secreting neurons that have a normal
GnRH content, which demonstrates that KISS1R affects either the
processing or release of this hormone but not the migration of
GnRH neurons.47,48 Several studies have demonstrated the ability
of kisspeptin to elicit the release of LH and FSH in different
animal species48–54 and in humans.55 This effect is mediated by
the KISS1–KISS1R interaction because it is not present in the
Kiss1r KO mice and is GnRH release-dependent; it is not directly
due to kisspeptin action on the pituitary because it is inhibited by
the co-administration of GnRH antagonist.49,50,56 Furthermore,
multiple independent mouse knockouts of Kiss1r and Kiss1 have
been described, and all of them recapitulate the human nICH
phenotype, which confirms that KISS1/KISS1R are robust proximal
regulators of GnRH release.57 KISS1-secreting neurons are also
highly responsive to oestrogen, and they have been implicated in
both the negative and positive central feedback of sex steroids to
GnRH production.58–60 In 2003, using linkage mapping in familial
nICH, two different groups simultaneously discovered the presence
of a loss-of-function mutation in KISS1R as genetic cause of
nICH.47,61 Further reports of human loss-of-function mutations
in KISS1R that were associated with autosomal recessive nICH have
been published in recent years, although this genetic cause of nICH
appears to be extremely rare.62 Considering the demonstrated import-
ance of the KISS1–KISS1R complex in the control of pubertal onset,
the KISS1 gene is another obvious candidate for genetic screening in
cases of ICH. Nevertheless, no pathogenic KISS1 mutations in asso-
ciation with ICH have been reported to date.
TACR3 and TAC3
The application of the strategy of studying nICH in rare consanguin-
eous families with multiple affected members and no mutations in
known ICH-related genes led to the identification of three different
loss-of-function mutations in TACR3 (OMIM number: 152332),
which is the gene located on chromosome 4q25 that encodes NK3R,
and one mutation in TAC3 (OMIM number: 162330), which is the
gene that is located on chromosome 12q13–q21 and encodes NKB,
which is the endogenous ligand of NK3R.63,64 Following these
initial studies, defects in either TACR3 or TAC3 were found in
several patients; this demonstrates that intact function of the
NKB/NK3R system is required for normal HPG activation at
puberty. Moreover, the association of the TACR3 mutation with
micropenis and cryptorchidism in male patients indicates that an
intact NKB/NK3R function is required for normal foetal gonado-
trophin secretion. NKB is a member of the tachykinin superfamily
of neuropeptides that also includes substance P and neurokinin A.65
NK3R, which is a GPCR, is primarily expressed in the central
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nervous system and is the most selective one of the tachykinin
receptors; it preferentially binds and is activated by NKB.66,67 The
mechanism(s) by which mutations in the NKB pathway exert their
effects on central neuroendocrine control of puberty and reproduc-
tion in humans is unclear.62 NKB is expressed in the arcuate nucleus
of hypothalamus neurons that project to GnRH secreting; here,
kisspeptin is also expressed, and both peptides in the arcuate are
downregulated by oestrogen. On the basis of these data, it is tempt-
ing to consider that kisspeptin and NKB play similar roles in relay-
ing feedback from sex steroids to GnRH production. However,
other observations seem to indicate important differences in their
actions, such as the different ability to stimulate GnRH release in
different species (kisspeptin can stimulate this release in almost all
species, but NKB cannot), or the different phenotypes that have
been observed in KO mice models of kisspeptin or NKB resistance,
which are associated with a classic ICH phenotype67 or grossly nor-
mal fertility,68 respectively. NKB has a wider pattern of central
nervous system expression than KISS1,69 which suggests that the
arcuate may not be the sole, or even the most important, site at
which NKB exerts its influence on reproductive function. Moreover,
the investigations in mutation-carrying patients at several devel-
opmental windows demonstrated that variants in the NKB pathway
can profoundly impact the function of the HPG axis in late gesta-
tion; however, the effect of these same mutations appears to become
attenuated over time with the partial or complete reversal of hypo-
gonadotropism in adult life.
GnRHR and GnRH
While the most obvious autosomal candidate gene for GnRH defi-
ciency is the GnRH gene itself (OMIM number: 152760), which is
located on 8p21–8p11.2, it was only in 2009 that the first genetic
defects in the GNRH1 gene were reported.70,71 GnRH, which acts
via the GnRH receptor, is one of the most important factors within
the HPG axis, and it has long been the most obvious candidate gene to
produce a purely functional defect in its activity. This is in accordance
with the phenotype that is apparent in the hypogonadal (hpg) mouse
experimental model, in which CH is linked to an autosomal recessive
mutation in the GnRH gene and results in the complete absence of
GnRH synthesis.72,73 Hpg mice are sexually infantile, infertile and
present a hormone profile that is characterized by low sex steroid
and gonadotrophin levels.73 In addition to their reproductive
deficits, these mice present a phenotype that is grossly normal with
the exception of abnormal tooth maturation and biomineralisation.74
Moreover, the reproductive deficits of the hpg mice were completely
reversed and theGnRHexpressionwas restored by gene therapy.72 The
second factor in this receptor–ligand pair is GnRHR, in which genetic
defects began to be described 15 years ago in ICH patients.75 The
GnRHR gene (OMIM number: 138850), which is located on chro-
mosome 4q21.2, encodes a seven transmembrane-spanning GPCR.
The activation of GnRHR results in the increased activity of phospho-
lipase C and the mobilisation of intracellular calcium by means of the
Gq/G11 group of G proteins. NullGnrhrmicemodels display a similar
phenotype to clinical ICH syndrome. A more severe phenotype was
observed in the gene trap Gnrhr-null mouse model76 compared with
the N-ethyl-N-nitrosourea-induced model,77 and they display small
sexual organs with low LH/FSH and sex steroid levels, the failure of
sexual maturation, infertility and the inability to respond to exogen-
ous GnRH. Following the initial report in humans, several additional
GnRHR mutations have been described, including mutations in the
transmembrane domains, which significantly impair GnRH binding
and/or signalling.15 These variable genotypes result in a wide pheno-
typic spectrum that ranges from fertile eunuch syndrome and partial
idiopathic hypogonadotropic hypogonadism to the most complete
form of GnRH resistance that is characterized by cryptorchidism,
micropenis, undetectable gonadotrophins and the absence of pubertal
development.78 Nevertheless, both GnRH1 and GnRHR defects pro-
duce classic isolated nICH without any associated developmental
defects.62
CHD7
CHARGE syndrome (colobomata, heart anomalies, choanal atresia,
retardation, genital and ear anomalies) is a multisystem autosomal
dominant syndrome that shares overlapping features of ICH and
hyposmia with KS. CHARGE syndrome is caused by a mutation in
the CHD7 gene (chromodomain helicase DNA-binding protein 7;
OMIM number: 608892), which is located on chromosome 8q12.1.
A CHD7 genetic screen in a series of ICH/KS patients demonstrated
a mutational prevalence of 6%, which therefore suggested that KS/
ICH were mild allelic variants of CHARGE syndrome and might be
caused by CHD7 gene mutations;79 CHD7 is also known as KAL5.
Further studies have demonstrated that CHD7 mutations may be
present in KS patients who had additional features of the
CHARGE syndrome phenotype.80 Thus, CHD7 genetic screening
may be considered for KS/ICH patients who present special features,
such as deafness, dysmorphic ears and/or hypoplasia or aplasia of the
semicircular canals.
NELF
The Nelf (nasal embryonic LH-releasing hormone factor) protein was
first isolated in mouse, and the expression patterns of the Nelf gene in
the olfactory axons andGnRH-secreting neurons during development
are consistent with its function as a migratory factor for GnRH neu-
rons.81,82 However, although rare sequence variants have been
reported in KS patients,29,83–85 no functional studies have been
reported thus far.
EBF2
The Ebf2 gene plays a key role in the neuroendocrine axis as proposed
by Corradi et al.86 In Ebf2-null mutants, because of the defective
migration of gonadotrophin-releasing, hormone-synthesising neu-
rons, the formation of the neuroendocrine axis is impaired; this leads
to secondary hypogonadism. To date, no mutations have been
reported in the human series of KS/nICH.87
CRITICAL ASPECTS OF ICH PHENOMICS AND GENOMICS
ICH has been classically classified into two distinct clinical entities, KS
and nICH. However, such separate classification has been questioned
in recent years, because these two entities may exist in different rela-
tives within unique familial settings, which therefore supports the idea
that they may constitute different phenotypic manifestations of the
same genetic defect.26,28,75,88–90 On the basis of this possibility, a novel
idea is that ICHmay be considered to be a complex genetic disease that
is characterized by variable expressivity, penetrance and modes of
inheritance. As in multifactorial complex diseases, the pathogenesis
of ICH may include the influence of environmental factors, which
may exert epigenetic effects on gene expression, and the concurrent
involvement of single nucleotide polymorfisms or other genetic
defects in two or multiple interacting genes. Indeed, recent reports
of patients who harbour pathogenic rare variants in more than one
gene have challenged the long-held view of a strictly monogenic
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disorder. Oligogenicity, which is as frequent as the biallelic defects
in a single gene, may partially account for the phenotypic variability
of isolated GnRH deficiency.29 Furthermore, the gene–environment
interaction is supported by: (i) the presence of rare variants in
genes for isolated GnRH deficiency in unaffected patients, which
suggests that such variants may also underlie milder forms of
GnRH deficiency when combined with environmental factors,
which was recently described in a series of patients with acquired
hypothalamic amenorrhea and heterozygous rare variants in
FGFR1, KAL1, PROKR2 and GnRHR;91 (ii) the occasional adult
onset of ICH following normal puberty and reproductive func-
tion;92,93 and (iii) the reversal of ICH in a subset of patients who
experience an extremely delayed onset of a spontaneous GnRH
function during the withdrawal of steroid administration, which
can even occur beyond 25 years of age.94
THE ITALIAN NETWORK FOR ICH
Because of the involvement of numerous clinicians from several
Italian regions (see the list at the note of first page of the manuscript)
and thanks to the support of the Italian Societies of Endocrinology
and Paediatric Endocrinology and Diabetes, we were able to collect a
large series of patients who are affected with ICH. To date, we have
collected a total number of 227 ICH patients, which are 83% males
and 17% females and have either KS (43%; 1 female:6 males) or nICH
(57%; 1 female:4 males). The most important clinical data are sum-
marized in Table 1.
Because genetic investigations that are aimed to reveal the possible
genetic cause of ICH in a single case are extremely expensive and
tedious and cannot be sustained by a single centre, we decided to
coordinate the efforts of several molecular biology laboratories in
Italy to set up an extensive service of genetic analyses that are aimed
to support counselling of families at risk. Therefore, because of the
contribution of the collaborating Italian centres, we began to screen
the entire coding regions of the most relevant candidate genes for ICH
pathogenesis. The current results are summarized in Table 2, and they
show the identification of a contributing genetic defect in approxi-
mately 35% of the patients. Genetic data from Italian patients show a
major involvement of KAL1, FGFR1 and PROKR2, and the rare
involvement of variants in the other candidate genes. Compared with
the data that have been reported in the literature, our series seem to
show a higher percentage of genetic alterations in the FGFR1 and
PROKR2 genes and a lower percentage in the GnRHR gene in the
nICH patients (see data in Table 2 and in Ref. 62). Of note, we have
not yet identified any alterations in the coding regions of GNRH1,
KISS1R, TAC3 and TACR3, although the screening of these genes was
so far accomplished in only a part of the entire cohort. Interestingly, in
our series, a digenic involvement was detected in three cases. Overall,
these data indicate that we can support genetic counselling for
approximately one-third of the affected families. Such an outcome
may be considered to be valuable because it can lead to the early
recognition and prepubertal treatment of several ICH cases.
Nevertheless, the genetic studies were negative in approximately
65% of the patients, which is similar to the results that have been
reported in the literature.
FUTURE PERSPECTIVES
Because two-thirds of ICH patients lack a clear molecular basis, new
strategic and methodological advances are needed to cover this gap.
The likely involvement of still-unknown candidate genes may be iden-
tified by the use of exome sequencing or genome-wide investigation
techniques. Moreover, the contributions of cryptic genetic defects that
are unresolved by direct sequencing or those of alterations in non-
genetic mechanisms that regulate gene expression (i.e., abnormal states
of gene methylation or micro-RNA defects) still remain to be eluci-
dated. Nevertheless, the accumulation of large consortia is required to
cover the elevated costs and collect sufficiently numerous cohorts to
increase the success rate of these experiments that investigate the whole
genome or the regulatory mechanisms without any prior selection.
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Table 1 Primary clinical features of the Italian ICH series
KS nICH Total
Groups (n and sex distribution %) 97 (43%) (1 male; 6 females) 130 (57%) (1 male; 4 females) 227 (male: 83%; female: 17%)
Age at diagnosis (years, range) 2–45 13–61 —
Familial cases 20/97 (20.0%) 17/130 (13.0%) 37/227 (16.2%)
Midline defects 12/97 (12.3%) 3/130 (2.3%) 15/227 (6.6%)
Bimanual synkinesis 4/97 (4.1%) 0/130 4/227 (1.7%)
Renal agenesia/aplasia 3/97 (3.1%) 1/130 (0.7%) 4/227 (1.7%)
Hearing defects 2/97 (2.1%) 0/130 2/227 (0.8%)
Cryptorchidism 29/83 (35.0%) (monolateral: 14; bilateral: 15) 11/105 (10.0%) (monolateral: 3; bilateral: 9) 40/188 (21.2%) (monolateral: 17; bilateral: 24)
Abbreviations: ICH, idiopathic central hypogonadism; KS, Kallmann syndrome; nICH, normo-osmic ICH.
Table 2 Results of the analyses of the principal candidate genes in the Italian ICH series
Fgfr1 Fgf8 Prok2 ProkR2 Kal1 GnRHR GnRH1 KissR1 Tac3 TacR3 Ebf2
KS 8/77 1/23 2/95 10/95 6/64 0/43 0/37 0/40 0/5 0/5 0/21













0/93 0/93 0/18 0/18 0/21
Abbreviations: ICH, idiopathic central hypogonadism; KS, Kallmann syndrome; nICH, normo-osmic ICH.
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